968 related articles for article (PubMed ID: 27828943)
1. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells.
De Henau O; Rausch M; Winkler D; Campesato LF; Liu C; Cymerman DH; Budhu S; Ghosh A; Pink M; Tchaicha J; Douglas M; Tibbitts T; Sharma S; Proctor J; Kosmider N; White K; Stern H; Soglia J; Adams J; Palombella VJ; McGovern K; Kutok JL; Wolchok JD; Merghoub T
Nature; 2016 Nov; 539(7629):443-447. PubMed ID: 27828943
[TBL] [Abstract][Full Text] [Related]
2. PI3Kγδ inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model.
Han MG; Jang BS; Kang MH; Na D; Kim IA
Eur J Cancer; 2021 Nov; 157():450-463. PubMed ID: 34601286
[TBL] [Abstract][Full Text] [Related]
3. PI3K/mTOR inhibition induces tumour microenvironment remodelling and sensitises pS6
De Wispelaere W; Annibali D; Tuyaerts S; Messiaen J; Antoranz A; Shankar G; Dubroja N; Herreros-Pomares A; Baiden-Amissah REM; Orban MP; Delfini M; Berardi E; Van Brussel T; Schepers R; Philips G; Boeckx B; Baietti MF; Congedo L; HoWangYin KY; Bayon E; Van Rompuy AS; Leucci E; Tabruyn SP; Bosisio F; Mazzone M; Lambrechts D; Amant F
Clin Transl Med; 2024 May; 14(5):e1655. PubMed ID: 38711203
[TBL] [Abstract][Full Text] [Related]
4. Inhibiting PI3 kinase-γ in both myeloid and plasma cells remodels the suppressive tumor microenvironment in desmoplastic tumors.
Zhang X; Shen L; Liu Q; Hou L; Huang L
J Control Release; 2019 Sep; 309():173-180. PubMed ID: 31362079
[TBL] [Abstract][Full Text] [Related]
5. Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer.
Lal JC; Townsend MG; Mehta AK; Oliwa M; Miller E; Sotayo A; Cheney E; Mittendorf EA; Letai A; Guerriero JL
Breast Cancer Res; 2021 Aug; 23(1):83. PubMed ID: 34353349
[TBL] [Abstract][Full Text] [Related]
6. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
7. Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade.
Huffaker TB; Lee SH; Tang WW; Wallace JA; Alexander M; Runtsch MC; Larsen DK; Thompson J; Ramstead AG; Voth WP; Hu R; Round JL; Williams MA; O'Connell RM
J Biol Chem; 2017 Nov; 292(45):18530-18541. PubMed ID: 28912267
[TBL] [Abstract][Full Text] [Related]
8. Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer.
Egelston C; Guo W; Yost S; Lee JS; Rose D; Avalos C; Ye J; Frankel P; Schmolze D; Waisman J; Lee P; Yuan Y
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33757987
[TBL] [Abstract][Full Text] [Related]
9. Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity.
Punt S; Malu S; McKenzie JA; Manrique SZ; Doorduijn EM; Mbofung RM; Williams L; Silverman DA; Ashkin EL; Dominguez AL; Wang Z; Chen JQ; Maiti SN; Tieu TN; Liu C; Xu C; Forget MA; Haymaker C; Khalili JS; Satani N; Muller F; Cooper LJN; Overwijk WW; Amaria RN; Bernatchez C; Heffernan TP; Peng W; Roszik J; Hwu P
Cancer Immunol Immunother; 2021 Apr; 70(4):1101-1113. PubMed ID: 33123754
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment.
Steggerda SM; Bennett MK; Chen J; Emberley E; Huang T; Janes JR; Li W; MacKinnon AL; Makkouk A; Marguier G; Murray PJ; Neou S; Pan A; Parlati F; Rodriguez MLM; Van de Velde LA; Wang T; Works M; Zhang J; Zhang W; Gross MI
J Immunother Cancer; 2017 Dec; 5(1):101. PubMed ID: 29254508
[TBL] [Abstract][Full Text] [Related]
11. Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo.
De Vera AA; Gupta P; Lei Z; Liao D; Narayanan S; Teng Q; Reznik SE; Chen ZS
Cancer Lett; 2019 Feb; 442():91-103. PubMed ID: 30391357
[TBL] [Abstract][Full Text] [Related]
12. Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.
Boshuizen J; Vredevoogd DW; Krijgsman O; Ligtenberg MA; Blankenstein S; de Bruijn B; Frederick DT; Kenski JCN; Parren M; Brüggemann M; Madu MF; Rozeman EA; Song JY; Horlings HM; Blank CU; van Akkooi ACJ; Flaherty KT; Boland GM; Peeper DS
Nat Commun; 2020 Aug; 11(1):3946. PubMed ID: 32770055
[TBL] [Abstract][Full Text] [Related]
13. Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer.
Zhang Y; Velez-Delgado A; Mathew E; Li D; Mendez FM; Flannagan K; Rhim AD; Simeone DM; Beatty GL; Pasca di Magliano M
Gut; 2017 Jan; 66(1):124-136. PubMed ID: 27402485
[TBL] [Abstract][Full Text] [Related]
14. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.
Mariathasan S; Turley SJ; Nickles D; Castiglioni A; Yuen K; Wang Y; Kadel EE; Koeppen H; Astarita JL; Cubas R; Jhunjhunwala S; Banchereau R; Yang Y; Guan Y; Chalouni C; Ziai J; Şenbabaoğlu Y; Santoro S; Sheinson D; Hung J; Giltnane JM; Pierce AA; Mesh K; Lianoglou S; Riegler J; Carano RAD; Eriksson P; Höglund M; Somarriba L; Halligan DL; van der Heijden MS; Loriot Y; Rosenberg JE; Fong L; Mellman I; Chen DS; Green M; Derleth C; Fine GD; Hegde PS; Bourgon R; Powles T
Nature; 2018 Feb; 554(7693):544-548. PubMed ID: 29443960
[TBL] [Abstract][Full Text] [Related]
15. Effective combinatorial immunotherapy for castration-resistant prostate cancer.
Lu X; Horner JW; Paul E; Shang X; Troncoso P; Deng P; Jiang S; Chang Q; Spring DJ; Sharma P; Zebala JA; Maeda DY; Wang YA; DePinho RA
Nature; 2017 Mar; 543(7647):728-732. PubMed ID: 28321130
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Haspin Kinase Promotes Cell-Intrinsic and Extrinsic Antitumor Activity.
Melms JC; Vallabhaneni S; Mills CE; Yapp C; Chen JY; Morelli E; Waszyk P; Kumar S; Deming D; Moret N; Rodriguez S; Subramanian K; Rogava M; Cartwright ANR; Luoma A; Mei S; Brinker TJ; Miller DM; Spektor A; Schadendorf D; Riggi N; Wucherpfennig KW; Sorger PK; Izar B
Cancer Res; 2020 Feb; 80(4):798-810. PubMed ID: 31882401
[TBL] [Abstract][Full Text] [Related]
17. CU06-1004-Induced Vascular Normalization Improves Immunotherapy by Modulating Tumor Microenvironment
Park S; Oh JH; Park DJ; Zhang H; Noh M; Kim Y; Kim YS; Kim H; Kim YM; Ha SJ; Kwon YG
Front Immunol; 2020; 11():620166. PubMed ID: 33584714
[TBL] [Abstract][Full Text] [Related]
18. Nanodrug modified with engineered cell membrane targets CDKs to activate aPD-L1 immunotherapy against liver metastasis of immune-desert colon cancer.
Ding D; Liang R; Li T; Lan T; Li Y; Huang S; He G; Ren J; Li W; Zheng Z; Chen T; Fang J; Huang L; Shuai X; Wei B
J Control Release; 2024 May; 369():309-324. PubMed ID: 38554771
[TBL] [Abstract][Full Text] [Related]
19. Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis.
Erkes DA; Cai W; Sanchez IM; Purwin TJ; Rogers C; Field CO; Berger AC; Hartsough EJ; Rodeck U; Alnemri ES; Aplin AE
Cancer Discov; 2020 Feb; 10(2):254-269. PubMed ID: 31796433
[TBL] [Abstract][Full Text] [Related]
20. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.
Paraiso KH; Haarberg HE; Wood E; Rebecca VW; Chen YA; Xiang Y; Ribas A; Lo RS; Weber JS; Sondak VK; John JK; Sarnaik AA; Koomen JM; Smalley KS
Clin Cancer Res; 2012 May; 18(9):2502-14. PubMed ID: 22351686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
